{"id":"abilify-mycite","safety":{"commonSideEffects":[{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"}]},"_chembl":{"chemblId":"CHEMBL1112","moleculeType":"Small molecule","molecularWeight":"448.39"},"_dailymed":{"setId":"e8787c3f-5e41-42d1-8091-44b56346620f","title":"ABILIFY MYCITE (ARIPIPRAZOLE) TABLET WITH SENSOR [OTSUKA AMERICA PHARMACEUTICAL, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole works by acting as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, helping to restore balance in neurotransmitter activity in the brain. The MyCite formulation includes an ingestible sensor that detects when the medication is ingested and transmits this information to a wearable patch and mobile app, enabling real-time monitoring of medication adherence. This digital health component is designed to improve treatment outcomes by providing patients, caregivers, and healthcare providers with objective adherence data.","oneSentence":"Abilify MyCite is an ingestible tablet formulation of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, equipped with an ingestible sensor that tracks medication adherence.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:51:46.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (acute manic or mixed episodes)"},{"name":"Major depressive disorder (adjunctive treatment)"}]},"trialDetails":[{"nctId":"NCT06372210","phase":"NA","title":"A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2023-06-26","conditions":"Mental Disorder, Schizophrenia, Major Depressive Disorder","enrollment":54},{"nctId":"NCT02091882","phase":"PHASE4","title":"Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-03-21","conditions":"Device Latency","enrollment":30},{"nctId":"NCT03892889","phase":"PHASE3","title":"A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2019-04-29","conditions":"Schizophrenia","enrollment":277}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["OPC-14597 Digital"],"phase":"marketed","status":"active","brandName":"Abilify MyCite®","genericName":"Abilify MyCite®","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abilify MyCite is an ingestible tablet formulation of aripiprazole, a dopamine D2 and serotonin 5-HT1A receptor partial agonist, equipped with an ingestible sensor that tracks medication adherence. Used for Schizophrenia, Bipolar I disorder (acute manic or mixed episodes), Major depressive disorder (adjunctive treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}